NAYA Biosciences operates a healthcare services fertility business as well as expand its focus to the development of first-in-class clinical-stage assets in oncology and autoimmune diseases... Show more
The RSI Oscillator for NAYA moved into overbought territory on March 04, 2025. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NAYA advanced for three days, in of 211 cases, the price rose further within the following month. The odds of a continued upward trend are .
NAYA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on March 04, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on NAYA as a result. In of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NAYA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for NAYA entered a downward trend on February 25, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.752) is normal, around the industry mean (23.546). P/E Ratio (0.054) is within average values for comparable stocks, (82.440). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (0.494) is also within normal values, averaging (41.434).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. NAYA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NAYA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Industry MedicalSpecialties
A.I.dvisor tells us that NAYA and ISPC have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NAYA and ISPC's prices will move in lockstep.
Ticker / NAME | Correlation To NAYA | 1D Price Change % | ||
---|---|---|---|---|
NAYA | 100% | -13.75% | ||
ISPC - NAYA | 30% Poorly correlated | -3.90% | ||
NEO - NAYA | 21% Poorly correlated | -2.51% | ||
XYLO - NAYA | 20% Poorly correlated | -1.81% | ||
ESTA - NAYA | 20% Poorly correlated | +7.74% | ||
TELA - NAYA | 11% Poorly correlated | N/A | ||
More |